EMAIL THIS PAGE TO A FRIEND

Lancet (London, England)

Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.


PMID 25468168

Abstract

The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major cardiovascular events (stroke, coronary heart disease, heart failure, and cardiovascular death). We used meta-analyses and meta-regressions to assess interactions between treatment and BMI when fitted as either a categorical variable (<25 kg/m(2), 25 to <30 kg/m(2), and ≥30 kg/m(2)) or a continuous variable. Analyses were based on 135,715 individuals from 22 trials who had 14,353 major cardiovascular events. None of the six primary comparisons showed evidence that protection varied by drug class across the three BMI groups (all p for trend >0·20). When analysed as a continuous variable, angiotensin-converting-enzyme inhibitors gave slightly greater protection for each 5 kg/m(2) higher BMI than did calcium antagonists (hazard ratio 0·93, 95% CI 0·89-0·98; p=0·004) or diuretics (0·93, 0·89-0·98; p=0·002). The meta-regressions showed no relation between BMI category and the risk reduction for a given fall in systolic blood pressure. By contrast with a previous report, we noted no relation between BMI and the efficacy of calcium antagonists compared with diuretics. We found little evidence that selection of a particular class of blood pressure-lowering drug will lead to substantially different outcomes for individuals who are obese compared with those who are lean. None.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

441872
Calcium, dendritic pieces, purified by distillation, 99.99% trace metals basis
Ca
596566
Calcium, dendritic pieces, purified by distillation, 99.9% trace metals basis
Ca
465895
Calcium, dendritic pieces, purified by distillation, 99.5% trace metals basis
Ca
215147
Calcium, granular, 99%
Ca
327387
Calcium, pieces, <1 cm, 99%
Ca
215414
Calcium, turnings, 99% trace metals basis
Ca
D2270
Dibutyl phthalate
C16H22O4
152439
Dibutyl phthalate, ReagentPlus®, ≥99%
C16H22O4
18281
Dibutyl phthalate, certified reference material, TraceCERT®
C16H22O4
D1010000
Dibutyl phthalate, European Pharmacopoeia (EP) Reference Standard
C16H22O4
524980
Dibutyl phthalate, 99%
C16H22O4
80100
Dibutyl phthalate, Selectophore
C16H22O4
36736
Dibutyl phthalate, PESTANAL®, analytical standard
C16H22O4
H4759
Hydrochlorothiazide, crystalline
C7H8ClN3O4S2
H2910
Hydrochlorothiazide, meets USP testing specifications
C7H8ClN3O4S2
H1200000
Hydrochlorothiazide, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
1314009
Hydrochlorothiazide, United States Pharmacopeia (USP) Reference Standard
C7H8ClN3O4S2
PHR1032
Hydrochlorothiazide, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8ClN3O4S2
Y0001494
Hydrochlorothiazide for peak identification, European Pharmacopoeia (EP) Reference Standard
C7H8ClN3O4S2
71649
Sodium phosphate dibasic dodecahydrate, BioXtra, ≥99.0% (T)
HNa2O4P · 12H2O
71650
Sodium phosphate dibasic dodecahydrate, puriss. p.a., crystallized, ≥99.0% (T)
HNa2O4P · 12H2O
04273
Sodium phosphate dibasic dodecahydrate, meets analytical specification of Ph. Eur., BP, E339, 98.5-101% (calc. to the dried substance)
HNa2O4P · 12H2O
71663
Sodium phosphate dibasic dodecahydrate, tested according to Ph.Eur.
HNa2O4P · 12H2O
30414
Sodium phosphate dibasic dodecahydrate, 99-101% (calc. to the dried substance)
HNa2O4P · 12H2O